PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System - PainReform (NASDAQ:PRFX)

PRF Technologies (Nasdaq: PRFX) said it is advancing DeepSolar Predict, an AI platform aimed at commercial launch to optimize renewable energy revenue. The company says the system combines localized weather forecasting, production forecasting, imbalance risk management, and storage/portfolio optimization with real-time market decision support, building on its NVIDIA Connect participation and a previously filed weather-modeling patent.

Ionis reported that Roche's Phase 3 study of sefaxersen showed a 43.1% reduction in proteinuria versus placebo in adults with IgA nephropathy, a statistically significant result. The drug was well tolerated, and Ionis may receive regulatory and sales milestones, as well as royalties, under its agreement with Roche.

Vertex Pharmaceuticals reported positive interim results from its Phase 3 RAINIER trial, showing that povetacicept reduced proteinuria by 49.8% compared to placebo. The FDA is reviewing the drug for accelerated approval with a PDUFA date of November 30, 2026.

IONIS PHARMACEUTICALS INC (IONS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN) – Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to p

Ionis Pharmaceuticals reported that Roche's Phase 3 IMAgINATION study showed sefaxersen reduced proteinuria by 43.1% compared to placebo at 37 weeks (P<0.0001) in adults with IgA nephropathy. The study's safety profile matched prior data, and it continues to Week 105 to assess eGFR change.

Roche and Ionis reported that sefaxersen, an experimental kidney drug, reduced urine protein by 43.1% versus placebo at 37 weeks in a Phase 3 study. The drug, designed for self-administration, aims to treat IgA nephropathy (IgAN). Ionis CEO Brett Monia stated the results support its potential to reduce long-term dialysis or kidney transplantation needs. Roche licensed sefaxersen from Ionis and will share data with health authorities.